AbbVie submits Biologics license application to USFDA for Telisotuzumab Vedotin
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression